

**DEPARTMENT OF THE AIR FORCE
TRIAL JUDICIARY**

UNITED STATES	R.C.M. 703(d)(3)(A)(i)
v.	NOTICE #1 –
	EXPERT TESTIMONY –
	DR. [REDACTED]
SSGT KINYADA J. JOHNSON 552d Operations Support Squadron (AETC) Tinker Air Force Base, OK	26 January 2026

1. Pursuant to Rules for Courts-Martial (R.C.M.) Rule 703(d)(3)(A)(i), the government provides this notice of anticipated testimony of Dr. [REDACTED].

2. The government intends to call Dr. [REDACTED] as a witness in its case-in-chief and, if necessary, in rebuttal and/or sentencing proceedings. The government intends to qualify Dr. [REDACTED] as an expert in the field of forensic toxicology (and practices and procedures for the Air Force Drug Testing Laboratory) and to offer relevant opinions.

3. In summary:

a. Dr. [REDACTED] will testify regarding her education, professional history, professional organization involvement, publication, and prior history of being qualified as an expert witness.

b. Dr. [REDACTED] will testify regarding her review of the Drug Testing Reports (DTRs) associated with Specimen ID F529-0048-245 (**B2502038001**), Specimen ID F529-0048-579 (**B2502425001**), Specimen ID F529-0048-628 (**B2502633001**), Specimen ID F529-0048-831 (**B2503018009**), Specimen ID F529-0049-023 (**B2503233088**), Specimen ID F529-0049-217 (**B2503447009**), Specimen ID F529-0049-260 (**B2503607001**), Specimen ID F529-0049-494 (**B2504021037**), Specimen ID F529-0049-752 (**B2504258002**), Specimen ID F529-0049-859 (**B2504448039**), Specimen ID F529-0050-018 (**B2504644002**), Specimen ID F529-0050-268 (**B2505103150**), Specimen ID F529-0051-089 (**B2506230003**). Dr. [REDACTED] will testify, based on her training, experience, and expertise, that delta-9 tetrahydrocannabinol (THC-9) was found in the accused's urine specimens and that the findings and machine reports are consistent with the presence of THC-9 in the accused's urine samples.

c. Dr. [REDACTED] will testify regarding her personal knowledge of the Air Force Drug Testing Laboratory (AFDTL)'s processes and procedures including the handling of specimens, chain of custody, qualification, training, and policies of AFDTL.

d. Dr. [REDACTED] will testify based on her training, experience, and professional expertise that THC-9 and its metabolites are not naturally found or produced in the human body.

She will testify how THC-9 and its metabolites are broken down in the human body. She will testify how THC-9 affects a person after introduction into the body. She will testify about whether the findings in the DTR reports are consistent with multiple uses, and regarding likely timeframes of when THC-9 was consumed. She will testify how the THC-9 cutoff level and reported concentration are sufficient to reasonably discount the possibility of unknowing ingestion and to indicate a reasonable likelihood that the user would have experienced the physical and psychological effects of the drug. She will testify that the testing methodology reliably detected the presence of THC-9 and reliably quantified the concentration of the drug or metabolite in the samples.

e. Dr. [REDACTED] will testify, based on her training, experience, and professional expertise, how accessible THC-9 is to any member of the public.

4. Please contact the undersigned with any questions or requests related to this notice. The government will provide additional notices if there are changes in experts or anticipated testimony.

[REDACTED]
JASON J. ZUMMO, Maj, USAF
Trial Counsel

CERTIFICATE OF SERVICE

I hereby certify that I delivered a copy of this R.C.M. 703(d)(3)(A)(i) Notice #1 – Expert Testimony – Dr. [REDACTED] on Defense Counsel via e-mail on 26 January 2026.

[REDACTED]
JASON J. ZUMMO, Maj, USAF
Trial Counsel